Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

Popular Searches

Looking for Something Else?

There is no panel matching the key "Alert---Site-Wide"

Clinical Trials Search Results

Search for

in

Accepting Participants (7)

Showing 1-7 of 7

Sorted By:

A-Z
Z-A

Previous Next

A042302:Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Ph III Eval of Fixed Duration Zanubrutinib + Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Prev. Untreated Older Pts w/ CLL/SLL
CABL001J1US01 (ASC4REAL-2): A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy
A Real-world CML Pt Disease Registry to Describe Pt Experience & Clinical Outcomes Among Pts W/ CML Receiving Approved 1st or 2nd Line TKI Therapy
EAP Obe-cel (AUTO1-OS1): Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia
Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia
KT-US-471-0140: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Provide access to axicabtagene ciloleucel for patients with a disease approved for treatment with axicabtagene ciloleucel, out of specification for commercial release.
KT-US-472-0141: Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel
Provide access to brexucabtagene autoleucel for patients with a disease approved for treatment, that is otherwise out of specification for commercial release.
MK1026-010:A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
Ph3 Study compare Efficacy&Safety of Nemtabrutinib (MK-1026) +Venetoclax VS Venetoclax + Rituximab in Pts w/ Relapsed/Refractory CLL/SLL Following at Least 1 PriorTherapy
TP-CA-009 Aquarius: A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients with Hematologic Malignancies
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients with Hematologic Malignancies

Previous Next